- Pasithea Therapeutics (KTTA, Financial) to present updated interim data from Phase 1 trial of PAS-004 at the 2025 ASCO Annual Meeting.
- Interim results show promising clinical activity, target engagement, and a favorable safety profile.
- Trial targets patients with MAPK pathway driven advanced solid tumors.
Pasithea Therapeutics (KTTA) announced it will present updated interim data from its Phase 1 clinical trial of PAS-004 at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago. The data, showcasing activity through cohorts 4A and 4B, will be presented on June 2, 2025, from 1:30 PM to 4:30 PM CDT.
The Phase 1 clinical trial (NCT06299839) involves a multi-center, open-label, dose escalation 3+3 study design. It evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PAS-004 in patients with MAPK pathway driven advanced solid tumors. These patients exhibit RAS, NF1, or RAF mutations, or have failed prior BRAF/MEK inhibitor treatments.
PAS-004 is a next-generation macrocyclic MEK inhibitor under development for neurofibromatosis type 1 (NF1) and other MAPK pathway driven conditions. The promising results seen in clinical activity, target engagement, and a favorable safety profile highlight PAS-004's potential as an effective treatment for NF1-related neurofibromas and other cancers driven by MAPK pathway dysregulation.
Pasithea's presentation at ASCO marks an important milestone, reflecting scientific interest and potential therapeutic promise of PAS-004. Attendees will have access to the detailed presentation and poster, further illuminating the clinical progress of this innovative treatment.
